Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C31H33F3N2O5S
CAS Number:
Molecular Weight:
602.66
NACRES:
NA.77
UNSPSC Code:
51111800
MDL number:
Product Name
Tipranavir, ≥98% (HPLC)
InChI
1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
InChI key
SUJUHGSWHZTSEU-FYBSXPHGSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Related Categories
Biochem/physiol Actions
HIV protease inhibitor that is highly potent against a variety of HIV strains and isolates in several cell culture systems
Tipranavir is a HIV protease inhibitor that is highly potent against a variety of HIV strains and isolates in several cell culture systems. Tipranavir inhibits the replication of viruses that are resistant to other protease inhibitors.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S M Poppe et al.
Antimicrobial agents and chemotherapy, 41(5), 1058-1063 (1997-05-01)
PNU-140690 is a member of a new class of nonpeptidic human immunodeficiency virus (HIV) protease inhibitors (sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones) discovered by structure-based design. PNU-140690 has excellent potency against a variety of HIV type 1 (HIV-1) laboratory strains and clinical isolates, including
Manabu Aoki et al.
Journal of virology, 86(24), 13384-13396 (2012-09-28)
Tipranavir (TPV), a protease inhibitor (PI) inhibiting the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates. When a mixture of 11 multi-PI-resistant (but TPV-sensitive) clinical isolates (HIV(11MIX)), which included HIV(B) and HIV(C), was selected
Soo-Yon Rhee et al.
Antimicrobial agents and chemotherapy, 54(10), 4253-4261 (2010-07-28)
The effects of many protease inhibitor (PI)-selected mutations on the susceptibility to individual PIs are unknown. We analyzed in vitro susceptibility test results on 2,725 HIV-1 protease isolates. More than 2,400 isolates had been tested for susceptibility to fosamprenavir, indinavir
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service